HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanguinaria oral care safety

This article was originally published in The Rose Sheet

Executive Summary

Sanguinaria extract in oral hygiene products "may not be safe or even desirable to use," Boston University Oral and Maxillofacial Pathology Professor Sadru Kabani states in July 21 comments to FDA regarding advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products. Kabani bases comments on observations made clinically and microscopically since 1995, including experience with 15-20 patients who have developed oral leukoplakia and notes, "current research suggests that sanguinaria may have a possible role in the pathogenesis of these oral changes." Research on the ingredient up to the end of 1998 on which FDA based its recommendations "appeared in non-peer reviewed journals based on studies for a short duration of time," Kabani adds. Sanguinaria was included as Category I for safety in the ANPR released in May (1"The Rose Sheet" June 2, 2003, p. 3)...
Advertisement

Related Content

Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
Advertisement
UsernamePublicRestriction

Register

RS011415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel